{
    "info": {
        "nct_id": "NCT03600441",
        "official_title": "Open-label, Single-Arm, Phase 2 Study of Oral HDAC-inhibitor Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER)",
        "inclusion_criteria": "* Is able to understand and voluntarily sign an informed consent document before any study related assessments/procedures are conducted.\n* Has histologically confirmed Grade 1, 2, or 3a follicular lymphoma.\n* Has follicular lymphoma that has relapsed after (progressed after 6 months from the start of therapy) or is refractory to the last line of therapy (no response or progression within 6 months from the start of therapy) and needs treatment (must have at least 1 lymph node or extranodal lymphoid malignancy radiologically measuring ≥ 3 cm in its longest diameter).\n* Female patients must fulfil the following criteria:\n\n  a. Be of non-childbearing potential, defined as follows: i. Postmenopausal (ie, ≥ 1 year without any menses) prior to Screening, or ii. Documented surgically sterile (≥ 1 month prior to Screening)\n* Male patients must agree not to donate sperm starting from the time of Screening, throughout the study, and until after 90 days following the last dose.\n* Use highly effective forms of birth control (women of childbearing potential only), which include the following:\n\n  i. Consistent and correct use of established oral contraception ii. Established intrauterine device or intrauterine system iii. Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.\n* Female patients must agree not to breastfeed starting from the time of Screening, throughout the study, and until after 90 days following the last dose.\n* Male patients and their female spouse/partners who are of childbearing potential must use highly effective contraception methods consisting of 2 forms of birth control (at least 1 of which must be a barrier method) from the time of Screening, throughout the study, and until after 90 days following the last dose.\n* Male patients must agree not to donate sperm starting from the time of Screening, throughout the study, and until after 90 days following the last dose.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Has diagnosis of Grade 3b follicular lymphoma, or transformation to diffuse large B-cell lymphoma\n* Has a history of central nervous system lymphoma (either primary or secondary).\n* Has had prior treatment with abexinostat.\n* Has had allogeneic stem cell transplant within the last 6 months, or autologous stem cell transplant within the last 3 months before enrollment\n* Has any types of cardiac impairment at the time of enrollment\n* Has received any investigational medication within 30 days or 5 half-lives prior to Day 1, whichever is longer\n* Has prior history of malignancies, other than follicular lymphoma, unless the patient has been free of the disease for ≥ 3 years",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "i. Consistent and correct use of established oral contraception ii. Established intrauterine device or intrauterine system iii. Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.",
            "criterions": [
                {
                    "exact_snippets": "Consistent and correct use of established oral contraception",
                    "criterion": "oral contraception",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": "consistent and correct"
                        },
                        {
                            "requirement_type": "establishment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Established intrauterine device or intrauterine system",
                    "criterion": "intrauterine device or intrauterine system",
                    "requirements": [
                        {
                            "requirement_type": "establishment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository",
                    "criterion": "barrier methods of contraception",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "condom",
                                "occlusive cap (diaphragm or cervical/vault caps)"
                            ]
                        },
                        {
                            "requirement_type": "use with spermicide",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female patients must agree not to breastfeed starting from the time of Screening, throughout the study, and until after 90 days following the last dose.",
            "criterions": [
                {
                    "exact_snippets": "Female patients must agree not to breastfeed starting from the time of Screening, throughout the study, and until after 90 days following the last dose.",
                    "criterion": "breastfeeding",
                    "requirements": [
                        {
                            "requirement_type": "agreement to abstain",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration of abstinence",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "Screening to 90 days after last dose"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has follicular lymphoma that has relapsed after (progressed after 6 months from the start of therapy) or is refractory to the last line of therapy (no response or progression within 6 months from the start of therapy) and needs treatment (must have at least 1 lymph node or extranodal lymphoid malignancy radiologically measuring ≥ 3 cm in its longest diameter).",
            "criterions": [
                {
                    "exact_snippets": "Has follicular lymphoma",
                    "criterion": "follicular lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "relapsed after (progressed after 6 months from the start of therapy) or is refractory to the last line of therapy (no response or progression within 6 months from the start of therapy)",
                    "criterion": "response to last line of therapy",
                    "requirements": [
                        {
                            "requirement_type": "relapsed",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "refractory",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "needs treatment (must have at least 1 lymph node or extranodal lymphoid malignancy radiologically measuring ≥ 3 cm in its longest diameter)",
                    "criterion": "lymph node or extranodal lymphoid malignancy size",
                    "requirements": [
                        {
                            "requirement_type": "count",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        },
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "cm"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Is able to understand and voluntarily sign an informed consent document before any study related assessments/procedures are conducted.",
            "criterions": [
                {
                    "exact_snippets": "Is able to understand ... informed consent document",
                    "criterion": "informed consent comprehension",
                    "requirements": [
                        {
                            "requirement_type": "comprehension",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "voluntarily sign an informed consent document",
                    "criterion": "informed consent signing",
                    "requirements": [
                        {
                            "requirement_type": "voluntary signing",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "a. Be of non-childbearing potential, defined as follows: i. Postmenopausal (ie, ≥ 1 year without any menses) prior to Screening, or ii. Documented surgically sterile (≥ 1 month prior to Screening)",
            "criterions": [
                {
                    "exact_snippets": "Be of non-childbearing potential",
                    "criterion": "childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "non-childbearing"
                        }
                    ]
                },
                {
                    "exact_snippets": "Postmenopausal (ie, ≥ 1 year without any menses) prior to Screening",
                    "criterion": "menopausal status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "postmenopausal"
                        },
                        {
                            "requirement_type": "duration without menses",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "year"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to Screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "Documented surgically sterile (≥ 1 month prior to Screening)",
                    "criterion": "surgical sterility",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "surgically sterile"
                        },
                        {
                            "requirement_type": "duration since surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "month"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to Screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Male patients must agree not to donate sperm starting from the time of Screening, throughout the study, and until after 90 days following the last dose.",
            "criterions": [
                {
                    "exact_snippets": "Male patients",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                },
                {
                    "exact_snippets": "must agree not to donate sperm starting from the time of Screening, throughout the study, and until after 90 days following the last dose",
                    "criterion": "sperm donation",
                    "requirements": [
                        {
                            "requirement_type": "agreement to abstain",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": [
                                "from the time of Screening",
                                "throughout the study",
                                "until after 90 days following the last dose"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Use highly effective forms of birth control (women of childbearing potential only), which include the following:",
            "criterions": [
                {
                    "exact_snippets": "Use highly effective forms of birth control (women of childbearing potential only)",
                    "criterion": "birth control use",
                    "requirements": [
                        {
                            "requirement_type": "effectiveness",
                            "expected_value": "highly effective"
                        },
                        {
                            "requirement_type": "applicability",
                            "expected_value": "women of childbearing potential only"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Male patients and their female spouse/partners who are of childbearing potential must use highly effective contraception methods consisting of 2 forms of birth control (at least 1 of which must be a barrier method) from the time of Screening, throughout the study, and until after 90 days following the last dose.",
            "criterions": [
                {
                    "exact_snippets": "Male patients",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                },
                {
                    "exact_snippets": "female spouse/partners who are of childbearing potential",
                    "criterion": "spouse/partner childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "of childbearing potential"
                        }
                    ]
                },
                {
                    "exact_snippets": "must use highly effective contraception methods consisting of 2 forms of birth control (at least 1 of which must be a barrier method) from the time of Screening, throughout the study, and until after 90 days following the last dose",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "number of methods",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "forms"
                            }
                        },
                        {
                            "requirement_type": "method type",
                            "expected_value": "at least 1 barrier method"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "from Screening, throughout the study, and until after 90 days following the last dose"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Male patients must agree not to donate sperm starting from the time of Screening, throughout the study, and until after 90 days following the last dose.",
            "criterions": [
                {
                    "exact_snippets": "Male patients must agree not to donate sperm starting from the time of Screening, throughout the study, and until after 90 days following the last dose.",
                    "criterion": "sperm donation",
                    "requirements": [
                        {
                            "requirement_type": "agreement to abstain",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "abstinence period",
                            "expected_value": [
                                "from the time of Screening",
                                "throughout the study",
                                "until after 90 days following the last dose"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female patients must fulfil the following criteria:",
            "criterions": [
                {
                    "exact_snippets": "Female patients",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has histologically confirmed Grade 1, 2, or 3a follicular lymphoma.",
            "criterions": [
                {
                    "exact_snippets": "histologically confirmed Grade 1, 2, or 3a follicular lymphoma",
                    "criterion": "follicular lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "grade",
                            "expected_value": [
                                "1",
                                "2",
                                "3a"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Has had prior treatment with abexinostat.",
            "criterions": [
                {
                    "exact_snippets": "Has had prior treatment with abexinostat",
                    "criterion": "prior treatment with abexinostat",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has prior history of malignancies, other than follicular lymphoma, unless the patient has been free of the disease for ≥ 3 years",
            "criterions": [
                {
                    "exact_snippets": "Has prior history of malignancies, other than follicular lymphoma",
                    "criterion": "prior history of malignancies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": {
                                "operator": "!=",
                                "value": 1,
                                "unit": "follicular lymphoma"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless the patient has been free of the disease for ≥ 3 years",
                    "criterion": "disease-free interval for prior malignancy",
                    "requirements": [
                        {
                            "requirement_type": "duration disease-free",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has had allogeneic stem cell transplant within the last 6 months, or autologous stem cell transplant within the last 3 months before enrollment",
            "criterions": [
                {
                    "exact_snippets": "allogeneic stem cell transplant within the last 6 months",
                    "criterion": "allogeneic stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "time since transplant",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "autologous stem cell transplant within the last 3 months",
                    "criterion": "autologous stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "time since transplant",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has any types of cardiac impairment at the time of enrollment",
            "criterions": [
                {
                    "exact_snippets": "any types of cardiac impairment at the time of enrollment",
                    "criterion": "cardiac impairment",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time",
                            "expected_value": "at the time of enrollment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has received any investigational medication within 30 days or 5 half-lives prior to Day 1, whichever is longer",
            "criterions": [
                {
                    "exact_snippets": "Has received any investigational medication within 30 days or 5 half-lives prior to Day 1, whichever is longer",
                    "criterion": "receipt of investigational medication",
                    "requirements": [
                        {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 30,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a history of central nervous system lymphoma (either primary or secondary).",
            "criterions": [
                {
                    "exact_snippets": "Has a history of central nervous system lymphoma (either primary or secondary)",
                    "criterion": "central nervous system lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has diagnosis of Grade 3b follicular lymphoma, or transformation to diffuse large B-cell lymphoma",
            "criterions": [
                {
                    "exact_snippets": "diagnosis of Grade 3b follicular lymphoma",
                    "criterion": "Grade 3b follicular lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "transformation to diffuse large B-cell lymphoma",
                    "criterion": "transformation to diffuse large B-cell lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "transformation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}